Think IPO. Think IPOX®.
Specialized solutions for investors seeking exposure to the companies shaping what comes next.
IPOX® International Index
Tracked byFirst Trust International Equity Opportunities ETF FPXI ETF ↗
Upcoming listings
TEK4 Group
Precision engineering
N4 Group
Sports Nutrition & Equipment
MSG Rangers
Professional hockey
MSG Knicks
Professional basketball
Mi Material Holding
Semiconductor materials
Tk Accelis Group
Materials distribution
Suzhou Dongshan Precision Manufacturing
Electronic components
Microintelligence
Industrial robotics
TNE Korea
Industrial turbomachinery
Toggle Holdings
Real Estate
Youngkwang
Ship and plant equipment
Lablup
AI infrastructure software
Allganize Holdings
Information & Communication
Estie
Real estate data
DIP Holding
Mixed-use real estate
15 upcoming listings
News
Reuters: IPOX® VP Kat Liu Comments on Iambic Therapeutics’ AI Drug Discovery Platform and IPO Valuation
Nvidia-backed Iambic Therapeutics is seeking to raise up to $159.4 million in its U.S. IPO, targeting a valuation of up to $805.8 million. IPOX® Vice President Kat Liu told Reuters that Iambic’s value depends primarily on its drug pipeline and prospects for approval and commercialization. The company uses AI to develop cancer treatments and plans to list on Nasdaq as “IAM,” as biotech attracts investor interest despite rising Treasury yields, market volatility, and geopolitical tensions affecting the broader IPO market.
Fortune: IPOX® VP Kat Liu Comments on Oura’s Postponed IPO and Valuation Questions
IPOX® VP Kat Liu was interviewed for Fortune on Oura’s decision to postpone its IPO, offering perspective on valuation concerns, deal structure, and investor expectations. Liu discussed how Oura’s positioning as either a digital-health platform or consumer hardware company could shape valuation views, while also noting the market signal created by a high proportion of secondary shares.
Reuters: IPOX® Associate Lukas Muehlbauer Comments on Airtel Money’s London IPO
Reuters reports that Airtel Money is targeting a valuation of approximately $7 billion in its London IPO, which could become the city’s largest offering since September 2025. IPOX® Associate Lukas Muehlbauer said the deal demonstrates London’s ability to attract sizable international listings while also reflecting a buyer’s market. He noted that companies must remain realistic about valuation as Airtel Money prepares to raise about $703 million through the sale of 270 million shares ahead of its October debut.
Reuters: IPOX® Associate Lukas Muehlbauer Comments on Oura IPO Delay and Market Conditions
Reuters reports that Oura postponed its planned U.S. IPO as market volatility and higher interest rates increased investor caution toward new listings. IPOX® Associate Lukas Muehlbauer commented that higher rates are making investors more selective, particularly on growth valuations, while noting that the IPO window remains open. He also highlighted reported demand for Oura’s offering, which was said to be around four times oversubscribed, and pointed to Anthropic’s planned IPO as an important upcoming market test.
Reuters: IPOX® VP Kat Liu Discusses Investor Selectivity in Accelevation’s AI Infrastructure IPO
Reuters reports that Accelevation is targeting a valuation of up to $5.37 billion in its U.S. IPO, seeking to raise up to $720 million. IPOX® Vice President Kat Liu said investors are becoming more selective as AI infrastructure offerings expand, focusing on companies’ value-chain positioning, backlog quality, and ability to convert demand into revenue, margins, and cash flow. Accelevation provides power distribution, cooling, and modular infrastructure for data centers supporting growing AI computing demand.
Barron's: IPOX® Founder Josef Schuster Comments on Retail Access to IPO Allocations
IPOX® CEO Josef Schuster commented in Barron's on how growing retail access to IPO allocations through platforms such as Robinhood, SoFi and Coinbase could influence short-term trading in newly listed companies. Discussing Oura’s upcoming IPO, Schuster noted that restrictions on future IPO access may discourage investors from quickly selling allocated shares, potentially affecting early trading dynamics. The article also highlighted IPOX®’s broader role in IPO market research and its index tracked by the First Trust US Equity Opportunities ETF.
A world of new listings.
A disciplined approach.
New listings reflect economic growth and innovation. Our services bring a disciplined approach to this evolving global universe through independent research, index licensing, portfolio management and tailored investment solutions.
Explore our services